Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Influenza-associated morbidity and mortality has not decreased in the last decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza vaccine, a high-dose (HD) trivalent, inactivated influenza vaccine was developed. METHODS: A multicenter, randomized, double-blind controlled study was conducted to compare HD vaccine (which contains 60 microg of hemagglutinin per strain) with the licensed standard-dose (SD) vaccine (which contains 15 microg of hemagglutinin per strain) in adults > or = 65 years of age. RESULTS: HD vaccine was administered to 2575 subjects, and SD vaccine was administered to 1262 subjects. There was a statistically significant increase in the rates of seroconversion and mean hemagglutination inhibition titers at day 28 after vaccination among those who received HD vaccine, compared with those who received SD vaccine. Mean postvaccination titers for individuals who received HD vaccine were 116 for H1N1, 609 for H3N2, and 69 for B strain; for those who received SD vaccine, mean postvaccination titers were as 67 for H1N1, 333 for H3N2, and 52 for B strain. The HD vaccine met superiority criteria for both A strains, and the responses for B strain met non-inferiority criteria. Seroprotection rates were also higher for those who received HD vaccine than for those who received SD vaccine vaccine, for all strains. Local reactions were more frequent in individuals who received HD vaccine, but the reactions were mild to moderate. CONCLUSIONS: There was a statistically significant increase in the level of antibody response induced by HD influenza vaccine, compared with that induced by SD vaccine, without an attendant increase in the rate or severity of clinically relevant adverse reactions. These results suggest that the high-dose vaccine may provide improved protective benefits for older adults. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00391053 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of the above formulations show slightly higher immunogenicity in the elderly compared to the standard trivalent inactivated vaccine.”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [161]
In the citing paper
“for some populations, such as older adults, a higher dose might be beneficial, as has been shown for the influenza vaccine69,70.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [69]
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodInfluenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodAntibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064 · cited 2×
“vaccine effectiveness are generally lower in older adults [1, 4-6].”
BackgroundResultHobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,002 · cited 2×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundGovaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly
Nichol, K. L., Nordin, J. D., Nelson, D. B., Mullooly, J. P., & Hak, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070844 · Cited by 656 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 543 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
DETERMINANTS OF IMMUNITY TO INFLUENZA INFECTION IN MAN
POTTER, C. W., & OXFORD, J. S. (1979) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a071545 · Cited by 452 · cited 1×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundVu, T., Farish, S., Jenkins, M., & Kelly, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00041-5 · Cited by 376 · cited 1×
“appears that efficacy is diminished in older age groups [18].”
BackgroundThe efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
Nichol, K. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00070-7 · Cited by 265
Cited by
Items 201–300 of 388
Precision immunization: a new trend in human vaccination
Jia, S., Li, J., Liu, Y., & Zhu, F. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1670123 · Cited by 18
Immune responses of meningococcal B outer membrane vesicles in middle-aged mice
de Lima, G. T., Rodrigues, T. S., Portilho, A. I., Correa, V. A., Gaspar, E. B., & Gaspari, E. D. (2020) · Pathogens and Disease · doi:10.1093/femspd/ftaa028 · Cited by 17
Weissman, Y. L., Cooper, L., Sternbach, N., Ashkenazi‐Hoffnung, L., & Yahav, D. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.08.028 · Cited by 21
Immunosenescence: implications for vaccination programs in the elderly
Bowdish, D. M. E., Loukov, D., & Naidoo, A. (2015) · Vaccine Development and Therapy · doi:10.2147/vdt.s63888 · Cited by 23
“The group receiving the high dose had antibody levels that were 12%–25% higher than the standard dose group for the three viral strains (H1N1, H3N2, and B).(82) In another study where trivalent split influenza vaccine (Sanofi) dose was doubled (from 15 μg to 30 μg) in the frail elderly, antibody V ac ci ne : D ev el o…”
Han, S. H., Woo, J. H., Weber, F., Kim, W. J., Peck, K. R., Kim, S.-I., Choi, Y. H., & Kim, J. M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25295 · Cited by 17
Burke, M., & Rowe, T. A. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2017.08.006 · Cited by 17
Moro, P. L., Arana, J. S. V., Cano, M. V., Menschik, D., Yue, X., Lewis, P., Haber, P., Martin, D., & Broder, K. R. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis256 · Cited by 16
“Consistent with prelicensure experience, fever, pain, and headache were among the most frequent adverse events reported after TIV-HD receipt [5].”
BackgroundAskar, M., Ali, K. A., Batke, M., Brugger, T., Falman, A., Robertson, A. H., Pérez, J. J., Johansen, K., de Jonge, J., Krause, T. G., et al. (2025) · Reviews in Medical Virology · doi:10.1002/rmv.70020 · Cited by 15
Veroniki, A. A., Thirugnanasampanthar, S. S., Konstantinidis, M., Dourka, J., Ghassemi, M., Neupane, D., Khan, P. A., Nincic, V., Corry, M., Robson, R. C., et al. (2024) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2023-112767 · Cited by 22
PALMU, A. A. I., Pépin, S., Syrjänen, R., Mari, K., Moore, T. M., Jokinen, J., Nieminen, H. P., Kilpi, T. M., Samson, S., & Bruijn, I. D. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13270 · Cited by 18
CpG Improves Influenza Vaccine Efficacy in Young Adult but Not Aged Mice
Ramírez, A., Co, M., & Mathew, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150425 · Cited by 16
“The Fluzone HighDose vaccine formulation made by Sanofi Pasteur which contains four times the active antigen content as in the conventional vaccine received by young adults, increased seroconversion rates from 30% to 50% to H1N1 in the elderly [26].”
MethodHollingsworth, R. C., PALMU, A. A. I., Pépin, S., Dupuy, M., Shrestha, A., Jokinen, J., Syrjänen, R., Nealon, J., Samson, S., & Bruijn, I. D. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.03.007 · Cited by 16
Do Vaccines Need a Gender Perspective? Influenza Says Yes!
Prada, L. S.-D., de Lejarazu-Leonardo, R. O., Castrodeza, J., Tamayo, E., Eirós-Bouza, J. M., & Sanz-Muñoz, I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715688 · Cited by 19
“Also, a clinical trial performed with influenza vaccination showed better performance of elderly women in achieving protective humoral responses compared to elderly men (29).”
BackgroundLoebermann, M., Voss, U., Meyer, S., Bosse, D., Fritzsche, C., Klammt, S., Frimmel, S., Riebold, D., & Reisinger, E. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070866 · Cited by 14
“The vaccine was generally well tolerated and the number of adverse events did not exceed rates found in other studies of seasonal influenza vaccines [10,16].”
ResultAntibody Responsiveness to Influenza: What Drives It?
Lin, X., Lin, F., Liang, T., Ducatez, M., Zanin, M., & Wong, S. (2021) · Viruses · doi:10.3390/v13071400 · Cited by 16
Update on Vaccination Guidelines for Older Adults
Pilkinton, M. A., & Talbot, H. K. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13375 · Cited by 14
Statins and Influenza: Can We Move Forward?
Walsh, E. E. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir693 · Cited by 14
Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager‐Pedersen, M., Claggett, B. L., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.07.069 · Cited by 18
Seasonal influenza vaccination of high-risk adults
Loubet, P., Loulergue, P., Galtier, F., & Launay, O. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1188696 · Cited by 14
Manley, H. J., Lacson, E. K., Jr., Aweh, G. N., Li, N. C., Weiner, D. E., Miskulin, D. C., Hsu, C. M., Kapoian, T., Hayney, M. S., Meyer, K. B., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.01.425 · Cited by 15
Chan, T., Hung, I. F., Chan, K., Li, C. P.-Y., Li, P. T.-W., Luk, J. K.-H., Chu, L., & Chan, F. H.-W. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.05.002 · Cited by 13
Influenza among the elderly in the Americas: a consensus statement.
Rüttimann, R. W., Bonvehí, P., Vilar‐Compte, D., Istúriz, R., Labarca, J. A., & Vidal, E. I. D. O. (2013) · PubMed · Cited by 14
L’Huillier, A. G., Ferreira, V. H., Hirzel, C., Natori, Y., Slomovic, J., Ku, T., Höschler, K., Ierullo, M., Selzner, N., Schiff, J. R., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz471 · Cited by 13
B cell responses to the 2011/12-influenza vaccine in the aged
Kurupati, R. K., Kannan, S., Xiang, ■., Xiang, Z., Doyle, S. A., Ratcliffe, S. J., Schmader, K. E., & Ertl, H. C. J. (2013) · Aging · doi:10.18632/aging.100541 · Cited by 12
“These results are in contrast to a previous study, which reported increased antibody responses in the post pandemic phase to H1N1 vaccination [21] but in agreement with a study conducted in Singapore which also reported decreased responses to the H1N1 vaccine in aged individuals [22] and another study conducted prior…”
BackgroundResultAssessing the safety of influenza vaccination in specific populations: children and the elderly
Rowhani‐Rahbar, A., Klein, N. P., & Baxter, R. P. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.66 · Cited by 13
Introductory paper: High-dose influenza vaccine
Diaco, M., Chang, L.-J., Seet, B. T., Robertson, C., Chit, A., Mercer, M., Greenberg, D. P., Hollingsworth, R. C., & Samson, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2020.09.005 · Cited by 17
Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults
Shapiro, J. R., Morgan, R., Leng, S. X., & Klein, S. L. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.836642 · Cited by 13
“For influenza vaccines, studies that either control for or do not consider sex report that influenza vaccine immunogenicity (Falsey et al., 2009) and relative VE (DiazGranados et al.”
BackgroundMcGrath, L. J., Layton, J. B., Krueger, W. S., Kshirsagar, A. V., & Butler, A. M. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.079 · Cited by 12
“Similarly, there is a lack of data on the safety of this vaccine in the dialysis population; while one would expect similar rates of mild adverse events as seen in the general older population [20], there have been no large-scale safety studies in the dialysis population.”
BackgroundChanging Face of Vaccination in Immunocompromised Hosts
O’Shea, D., Widmer, L. A., Stelling, J., & Egli, A. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0420-2 · Cited by 13
Plant, E. P., Eick-Cost, A. A., Ezzeldin, H., Sánchez, J. L., Ye, Z., & Cooper, M. J. (2018) · Vaccines · doi:10.3390/vaccines6030039 · Cited by 11
Generation, Characterization, and Applications of Influenza A Reporter Viruses
Chiem, K., Nogales, A., & Martínez‐Sobrido, L. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2453-1_19 · Cited by 11
Atanasov, V. A., Barreto, N., Whittle, J., Meurer, J., Weston, B. W., Luo, Q., Yuan, A. Y., Franchi, L., Zhang, R., & Black, B. S. (2023) · Vaccines · doi:10.3390/vaccines11050971 · Cited by 12
Zhong, S., Ng, T. W. Y., Skowronski, D. M., Iuliano, A. D., Leung, N., Perera, R. A. P. M., Ho, F. C. S., Fang, V. J., Tam, Y. H., Ip, D., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad497 · Cited by 12
Influenza vaccination for older adults
Talbot, H. K., Libster, R., & Edwards, K. M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.18129 · Cited by 14
Infection Prevention and the Medical Director: Uncharted Territory
Kapoian, T., Meyer, K. B., & Johnson, D. S. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06050614 · Cited by 11
Sex Differences in Influenza Virus Infection, Vaccination, and Therapies
Peretz, J., Hall, O. J., & Klein, S. L. (2015) · Springer eBooks · doi:10.1007/978-3-319-16438-0_6 · Cited by 15
“Sex differences in HAI titers to high-dose TIV are still apparent, with antibody responses against each of the three influenza antigens being significantly higher in old females compared with age-matched males (Falsey et al. 2009).”
ResultLayton, J. B., McGrath, L. J., Sahrmann, J. M., Ma, Y., Dharnidharka, V. R., O’Neil, C. A., Weber, D. J., & Butler, A. M. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.06.020 · Cited by 11
“The findings of the current analysis are consistent with the results of phase 2 and 3 clinical studies comparing HDV and SDV in the general population of adults, which have reported increased occurrence of adverse events such as erythema [9], localized pain [6, 8, 9, 14], and myalgia [6, 8, 9] for the more immunogenic…”
ResultDiagnostic and therapeutic challenges of chronic obstructive pulmonary disease in the elderly
Allen, B., & Aboussouan, L. S. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000750 · Cited by 11
Bhat, S., Farraye, F. A., Hayney, M. S., & Caldera, F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.026 · Cited by 13
Effective Immunization of Older Adults Against Seasonal Influenza
Schaffner, W., Chen, W. H., HOPKINS, R. H., & Neuzil, K. M. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.02.019 · Cited by 14
Vaccine-Preventable Diseases in Older Adults
Al-Jabri, M., Rosero, C., & Saade, E. (2023) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.09.009 · Cited by 11
Naleway, A. L., Kim, S. S., Flannery, B. L., Levine, M. Z., Murthy, K., Sambhara, S. R., Gangappa, S., Edwards, L., Ball, S. W., Grant, L., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad223 · Cited by 12
Smith, L. R., Wodal, W., Crowe, B. A., Kerschbaum, A., Bruehl, P., Schwendinger, M. G., Savidis-Dacho, H., Sullivan, S. M., Shlapobersky, M., Hartikka, J., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24209 · Cited by 10
“Randomized controlled trials in ≥ 65 y old subjects have demonstrated superior or noninferior (depending upon the strain tested) serum HI immune responses with high dose TIV (60 μg; 4-fold higher HA/strain) or intradermal injection of standard dose TIV using a microinjection system.(10,11) Adjuvants are designed to st…”
MethodChristian, L. M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.075 · Cited by 13
Triggering of Toll-like Receptors in Old Individuals. Relevance for Vaccination
Zareian, N., Aprile, S., Cristaldi, L., Ligotti, M. E., Vasto, S., & Farzaneh, F. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191111155800 · Cited by 11
Vanderven, H. A., Barr, I., Reynaldi, A., Wheatley, A. K., Wines, B. D., Davenport, M. P., Hogarth, P. M., & Kent, S. J. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.01.066 · Cited by 11
Evaluation of Immune Responses to Influenza Vaccination in Chronic Obstructive Pulmonary Disease
Burel, J. G., & Pritchard, A. L. (2013) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.s4-001 · Cited by 10
Boosting effect of high-dose influenza vaccination on innate immunity among elderly
Bonduelle, O., Delory, T., Moscardini, I. F., Ghidi, M., Bennacer, S., Wokam, M., Lenormand, M., Petrier, M., Rogeaux, O., de Bernard, S., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.184128 · Cited by 9
Jaishwal, P., Jha, K., & Singh, S. P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134012 · Cited by 12
General Characteristics of Adjuvants and Their Mechanism of Action (Part 1)
Александровна, А. Н., Авдеева, Ж. И., Lysikova, S. L., Golovinskaya, O. V., & Александровна, Г. Л. (2020) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2020-20-4-245-256 · Cited by 12
“Об этом свидетельствуют результаты, полученные при вакцинации против вирусов гриппа или пневмонии лиц старше 65 лет [6].”
Moving Toward Improved Influenza Vaccines
Monto, A. S. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw644 · Cited by 11
Akmatov, M. K., Riese, P., Trittel, S., May, M., Prokein, J., Illig, T., Schindler, C., Guzmán, C. A., & Peßler, F. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4214-x · Cited by 8
Racial disparities in influenza vaccination
Sundaram, M. E., & Pamplin, J. R. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00027-1 · Cited by 9
Khan, T., Heffron, C. L., High, K. P., & Roberts, P. C. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0119 · Cited by 11
Tambyah, P. A. (2008) · Respirology · doi:10.1111/j.1440-1843.2008.01257.x · Cited by 9
The Imperative of Influenza Vaccines for Elderly Individuals—An Evolving Story
Poland, G. A., & Mulligan, M. J. (2009) · The Journal of Infectious Diseases · doi:10.1086/599791 · Cited by 9
“offers important and timely confirmatory data in a large phase 3 trial [22].”
BackgroundEssink, B. J., Vermeulen, W., Andrade, C., de Rooij, R., Isakov, L., Casula, D., & Albano, F. R. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126791 · Cited by 8
Pareek, M., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager‐Pedersen, M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf678 · Cited by 8
Aguilar, C., Husain, S., & Lortholary, O. (2018) · F1000Research · doi:10.12688/f1000research.14262.1 · Cited by 10
Special Considerations for Vaccines and the Elderly
Saade, E., Canaday, D. H., Davidson, H. E., Han, L., & Gravenstein, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00003-3 · Cited by 10
Sanchez, L., Nakama, T., Nagai, H., Matsuoka, O., Inoue, S., Inoue, T., Shrestha, A., Pandey, A., Chang, L.-J., & Bruijn, I. D. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.071 · Cited by 9
Treanor, J. J. (2023) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_19-2 · Cited by 10
Self-citationSuzuki, M., Torii, Y., Kawada, J., Kimura, H., Kamei, H., Onishi, Y., Kaneko, K., Ando, H., Kiuchi, T., & Ito, Y. (2013) · Microbiology and Immunology · doi:10.1111/1348-0421.12086 · Cited by 8
“Immune‐enhancing vaccine strategies, such as high‐dose vaccines (23, 24), booster dose re‐vaccination (25) or adjuvanted vaccines (26, 27) should be considered.”
Background2012-2013 Influenza update: Hitting a rapidly moving target
Jin, X. W., & Mossad, S. B. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12151 · Cited by 8
Influenza vaccine immunogenicity in patients with primary central nervous system malignancy
Strowd, R. E., III, Swett, K. R., Harmon, M. A., Carter, A. F., Pop-Vicas, A. E., Chan, M. D., Tatter, S. B., Ellis, T. L., Blevins, M. W., High, K. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou051 · Cited by 8
“When comparing these data with published seroconversion and seroprotection rates in an elderly population, which has been previously reported to have substandard serologic response rates, there was no significant difference in seroconversion or seroprotection rates for the A/H1N1 and B strains between groups.(11) For…”
MethodResultFalkeborn, T., Hinkula, J., Olliver, M., Lindberg, A. A., & Maltais, A.-K. (2017) · Virology Journal · doi:10.1186/s12985-017-0698-4 · Cited by 9
“hemagglutinin (HA) contained in standard-dose vaccines [12, 13].”
Paudel, M. L., Mahmud, S. M., Buikema, A. R., Korrer, S., Voorhis, D. V., Brekke, L. N., & Chit, A. (2019) · Vaccine · doi:10.1016/j.vaccine.2020.05.020 · Cited by 8
van Kessel, G., Geels, M. J., de Weerd, S., Buijs, L., de Bruijni, M. A. M., Glansbeek, H. L., van den Bosch, J. F., Heldens, J. G. M., & van den Heuvel, E. R. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.023 · Cited by 8
Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023–2024 Season
Choi, Y. J., Song, J. Y., Wie, S., Lee, J., Lee, J. S., Jeong, H. W., Eom, J. S., Sohn, J. W., Choi, W. S., Nham, E., et al. (2025) · Vaccines · doi:10.3390/vaccines13020197 · Cited by 7
“Recent studies have shown that high-dose or adjuvanted influenza vaccines induce more effective immune responses in older adults than standard-dose vaccines [23–25].”
Chen, J., Hsieh, S., Hwang, S., Liu, C.-S., Li, X., Fournier, M., Yeh, T., Yin, J. K., & Samson, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.078 · Cited by 8
Magyar, C. T. J., Gretener, C. P., Baldi, P., Storni, F., Kim‐Fuchs, C., Candinas, D., Berzigotti, A., Knecht, M., Beldi, G., Hirzel, C., et al. (2024) · Clinical Transplantation · doi:10.1111/ctr.15312 · Cited by 9
The need for novel influenza vaccines in low- and middle-income countries: A narrative review
Spinardi, J., Thakkar, K. B., Welch, V., Jagun, O., & Kyaw, M. H. (2024) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2024.104465 · Cited by 9
Influenza Vaccines and Vaccination Strategies
Neuzil, K. M., & Ortiz, J. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00021-7 · Cited by 7
High-dose trivalent influenza vaccine: safety and immunogenicity
de Lejarazu, R. O., Martinón‐Torres, F., de Miguel, Á. G., Díez‐Domingo, J., & Margüello, E. R. (2020) · Revista Española de Quimioterapia · doi:10.37201/req/110.2020 · Cited by 9
“El estudio demostró que la inmunogenicidad (Razón de las GMT de la IHA) de la vacuna IIV3HD era superior (el límite inferior del IC 95%>1,5 a los 28 días postvacunación para las cepas A/H1N1 (1,7; IC 95% 1,6-1,8) y A/H3N2 (1,8; IC 95% 1,71,8) y la inmunogenicidad fue no inferior y mayor para la cepa B (1,3; IC 95% 1,2…”
BackgroundInfluentialNew enhanced influenza vaccines for older Australians: what promise do they hold?
Sheridan, S. L., Patel, C., Macartney, K. K., & Cheng, A. C. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00334 · Cited by 7
Burke, M. (2018) · Current Geriatrics Reports · doi:10.1007/s13670-018-0258-9 · Cited by 8
Kuipery, A., Mahamed, D., Nkongolo, S., D’Angelo, J. A., Valiente, A. J., Mehrotra, A., Chapman, W. C., Horton, P. J., McGilvray, I. D., Janssen, H. L. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818612 · Cited by 6
High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease
Bartholdy, K. V., Johansen, N. D., Janstrup, K. H., Modin, D., Nealon, J., Samson, S., Loiacono, M. M., Harris, R. C., Larsen, C. S., Jensen, A. M. R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.032 · Cited by 6
Seasonal influenza vaccination: Overcoming immunosenescence with enhanced vaccines
Boivin, W. A., Loeb, M. B., Openshaw, P., Ashraf, M., & Pawelec, G. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100662 · Cited by 10
High-dose trivalent influenza vaccine. Efficacy and effectiveness
de Miguel, Á. G., Margüello, E. R., Díez‐Domingo, J., de Lejarazu, R. O., Martinón‐Torres, F., & Departamento de Medicina Preventiva y Salud Pública, U. R. J. C. (2020) · Revista Española de Quimioterapia · doi:10.37201/req/043.2020 · Cited by 6
“Keitel et al. 2006 [39] 2001-02 A/H3N2 50 51 Couch et al. 2007 [38] 2004-05 A/H3N2 206 208 Falsey et al. 2009 [18] 2006-07 A/H3N2 2.575 1.262 DiazGranados et al. 2013 [14] 2009-10 A/H1N1pdm09 6.013 3.008 DiazGranados et al. 2014 [15, 20] 2011-12 2012-13 A/H3N2 15.892 15.911 Nace et al. 2014 [40]…”
InfluentialSeasonal influenza vaccinations: specialized products for different target groups
Monto, A. S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.025 · Cited by 6
Bufan, B., Arsenović-Ranin, N., Petrović, R., Zivkovic, I. P., Stoiljković, V., & Leposavić, G. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110857 · Cited by 6
Fragilité et infection chez le sujet âgé : quelles relations ?
Mazière, S., Gavazzi, G., & Paccalin, M. (2012) · Les cahiers de l année gérontologique · doi:10.1007/s12612-012-0255-4 · Cited by 7
Urayoshi, S., Matsumoto, S., Miyatani, H., & Yoshida, Y. (2014) · Clinical Case Reports · doi:10.1002/ccr3.177 · Cited by 7
“These adverse reactions are generally mild, the majority occurring within 48 h of vaccination and resolving within 2 or 3 days [4, 5].”
BackgroundHigh-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults
Chahine, E. B. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020935645 · Cited by 7
Wu, H., Miao, H., Xue, H., Topham, D. J., & Zand, M. S. (2014) · Statistics in Biosciences · doi:10.1007/s12561-014-9108-2 · Cited by 7
“Both animal models and human studies which make use of peripheral blood mononuclear cell (PBMC) sampling have long been used to study the immune response to influenza infection (Baer et al., 2010; Falsey et al., 2009; Halliley et al., 2010).”
Rivera‐Izquierdo, M., Verdejo-Iáñez, A., Morales-Portillo, A., González-Alcaide, M., Ramos‐Bossini, A. J. L., Martínez‐Ruiz, V., Fernández‐Martínez, N. F., Martín-delosReyes, L. M., Jiménez-Mejías, E., de Alba, I. G.-F., et al. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106538 · Cited by 8
Jordan, A. A., Mills, K. C., Sobukonla, T., KELLY, A. P., & Flood, M. (2021) · Cureus · doi:10.7759/cureus.18387 · Cited by 5
“For this reason, a high dosage of the influenza vaccine has been recommended for this cohort [7-9].”
BackgroundBiological Sex and Pregnancy Affect Influenza Pathogenesis and Vaccination
Creisher, P. S., Seddu, K., Mueller, A. L., & Klein, S. L. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_5 · Cited by 9
Chang, L.-J., Anderson, E. J., Jeanfreau, R. J., He, Y., Hicks, B., Shrestha, A., Pandey, A., Landolfi, V. A., & Bruijn, I. D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.014 · Cited by 5
On-label and off-label use of high-dose influenza vaccine in the United States, 2010–2012
McGrath, L. J., & Brookhart, M. A. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1011026 · Cited by 5
Immunogenicity, efficacy of inactivated/live virus seasonal and pandemic vaccines
Keitel, W. A., Neuzil, K. M., & Treanor, J. J. (2013) · Wiley eBooks · doi:10.1002/9781118636817.ch20 · Cited by 14
Self-citationHigh-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease
Bartholdy, K. V., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager‐Pedersen, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.005 · Cited by 6
de Looze, F., Essink, B. J., van Boxmeer, J., Andrade, C., de Rooij, R., Casula, D., Xing, R., Piedrahita-Tovar, M., & Albano, F. R. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128436 · Cited by 4
Urdy, S., Hanke, M., Marrero, A. I. T., Ratto, N., Jacob, E., Peyronnet, E., Gourlet, J.-B., Chaves, S. S., Thommes, E. W., Coudeville, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-72716-1 · Cited by 7
Billings, W. Z., Ge, Y., Knight, J., Hemme, H., Hammerton, S. M., Skarlupka, A. L., Cao, W., Shen, Y., Bahl, J., Thomas, P. G., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf003 · Cited by 4
The New Era of Comparative Effectiveness: Will Public Health End up Left Behind?
Saver, R. S. (2011) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2011.00613.x · Cited by 4
Overton, E. T. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir838 · Cited by 4
Okada, C., Fujieda, M., Fukushima, W., Ohfuji, S., Kondo, K., Maeda, A., Nakano, T., Kaji, M., & Hirota, Y. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.040 · Cited by 4
Hygiene, J. O. P. M. A. (2023) · PubMed Central · doi:10.15167/2421-4248/jpmh2022.63.4s1 · Cited by 6
Metadata
- Authors
- Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J.
- Affiliations
- University of Rochester Medicine (US)
- St. Louis VA Medical Center (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-15
- Volume
- 200
- Issue
- 2
- Pages
- 172-180
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2164949714
- Cited by
- 388
- References
- 22
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 12 · 2023: 20 · 2022: 15 · 2021: 24 · 2020: 25 · 2019: 33 · 2018: 25 · 2017: 22 · 2016: 23 · 2015: 25 · 2014: 32 · 2013: 34 · 2012: 24
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- high-dose influenza vaccine, standard-dose influenza vaccine, immunogenicity, older adults, seroconversion, hemagglutination inhibition titers, trivalent inactivated influenza vaccine, vaccine dose comparison, local adverse reactions, seroprotection rate
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Viral, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Humans, Influenza, Human, Influenza Vaccines, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.